Monopar Therapeutics Inc. Cash and Restricted Cash
Monopar Therapeutics Inc. (MNPR) had Cash and Restricted Cash of $5.73 million as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2023-05-11
- 2023-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.73M.
- 2022-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.19M.
- 2022-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.32M.
- 2022-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16.46M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2023-03-31 | $5.73M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $8.19M 10-Q · filed 2023-05-11 |
| 2022-09-30 | $14.32M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $16.46M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $17.82M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $20.30M 10-Q · filed 2023-05-11 |
| 2021-09-30 | $22.34M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $24.29M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $25.72M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $16.74M 10-K · filed 2023-03-23 |
| 2020-09-30 | $17.98M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $12.55M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $12.59M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $13.21M 10-K · filed 2022-03-24 |
| 2019-09-30 | $4.49M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $5.13M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $5.88M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $6.89M 10-K · filed 2021-03-25 |
| 2018-09-30 | $7.62M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $8.22M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $8.97M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $9.78M 10-K · filed 2020-03-27 |
| 2017-09-30 | $10.59M 10-Q · filed 2018-11-09 |
| 2017-06-30 | $4.28M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $3.55M 10-Q · filed 2018-05-11 |
| 2016-12-31 | $2.87M 10-K · filed 2019-02-26 |
| 2015-12-31 | $2.81M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |